<i>Apolipoprotein E</i> genotype and in vivo amyloid burden in middle-aged Hispanics.

Abstract

To examine in vivo amyloid burden in relation to <i>APOE</i>ε4 genotype in middle-aged Hispanics. We hypothesize higher amyloid levels among <i>APOE ε4</i> carriers vs <i>APOE ε4</i> noncarriers. This is a cross-sectional study in a community-based sample of 249 middle-aged Hispanics in New York City who underwent a 3T brain MRI and PET with the amyloid radioligand ¹⁸F-florbetaben. <i>APOE</i> genotype was the primary exposure. The primary outcome was amyloid positivity. The secondary outcome was subthreshold amyloid levels examined as a continuous variable. <i>APOE ε4</i> carriers (n = 85) had a higher frequency (15.3%) of amyloid positivity compared to <i>APOE ε4</i> noncarriers (n = 164, 1.8%). In the subthreshold group of amyloid-negative participants (n = 233), <i>APOE ε4</i> carriers (n = 72) had a 0.02 (95% confidence interval [CI] 0.01-0.04) higher global brain amyloid standardized uptake value ratio (SUVR) compared to <i>APOE ε4</i> noncarriers (n = 161). Compared to participants with the ε3/ε3 genotype, participants with ε4/ε4 had the highest frequency of amyloid positivity (28.6%), followed by those with ε3/ε4 (11%). Among amyloid-negative participants (n = 233), compared to participants with ε3/ε3 (n = 134), those with ε4/ε4 (n = 5) had a 0.12 (95% CI 0.07-0.17) higher global brain amyloid SUVR, and those with ε3/ε4 had a 0.02 higher SUVR (95% CI 0.003-0.04). Results were similar when a median split was used for elevated amyloid, when continuous amyloid SUVR was analyzed in all participants, and in nonparametric Mann-Whitney comparisons. Middle-aged Hispanic <i>APOE ε4</i> carriers have higher in vivo brain amyloid burden compared with noncarriers, as reported in non-Hispanics.